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Abstract
Macular pigment (MP) confers potent antioxidant and anti-inflammatory effects at the macula, and may therefore protect retinal tissue from the
oxidative stress and inflammation associated with ocular disease and ageing. There is a body of evidence implicating oxidative damage and
inflammation as underlying pathological processes in diabetic retinopathy. MP has therefore become a focus of research in diabetes, with recent
evidence suggesting that individuals with diabetes, particularly type 2 diabetes, have lower MP relative to healthy controls. The present review
explores the currently available evidence to illuminate the metabolic perturbations that may possibly be involved in MP’s depletion. Metabolic
co-morbidities commonly associated with type 2 diabetes, such as overweight/obesity, dyslipidaemia, hyperglycaemia and insulin resistance,
may have related and independent relationships with MP. Increased adiposity and dyslipidaemia may adversely affect MP by compromising the
availability, transport and assimilation of these dietary carotenoids in the retina. Furthermore, carotenoid intake may be compromised by the
dietary deficiencies characteristic of type 2 diabetes, thereby further compromising redox homeostasis. Candidate causal mechanisms to explain
the lower MP levels reported in diabetes include increased oxidative stress, inflammation, hyperglycaemia, insulin resistance, overweight/
obesity and dyslipidaemia; factors that may negatively affect redox status, and the availability, transport and stabilisation of carotenoids in
the retina. Further study in diabetic populations is warranted to fully elucidate these relationships.
Key words: HDL: Macular pigment: TAG: Oxidative stress: Inflammation
Introduction
The macula is an oval-shaped area at the centre of the retina
which consists of a dense collection of light-sensitive cone
cells responsible for central, high-resolution vision and colour
perception(1). At the centre of the macula lies the fovea, where
macular pigment (MP) is located. MP is comprised of three car-
otenoids: lutein, zeaxanthin and the retinal metabolite of
lutein, meso-zeaxanthin(2,3). Lutein and zeaxanthin are not
synthesised de novo in humans but are exclusively of dietary
origin, typically derived from a diet rich in coloured fruit and
vegetables(4), while meso-zeaxanthin can be generated by
conversion from retinal lutein(5) or may be obtained from
dietary sources such as trout and salmon(6). The highest con-
centration of MP is found in the receptor axon layer of the
foveola, while in the parafovea, MP is located in the inner
plexiform layers(7,8), an area of the retina which is primed
for the generation of reactive oxygen species (ROS) and con-
sequently, oxidative damage(9). These hydroxyl-carotenoids are
selectively located in the macula to the exclusion of all other
dietary carotenoids. Fig. 1 highlights the location of MP and the
macula within the eye.
MP has a number of important functions in the eye. Evidence
suggests that MP contributes to visual performance and/or expe-
rience, as it acts as an optical filter for blue light (peak absorption
approximately 460 nm)(3,10). The importance of MP’s antioxidant
and anti-inflammatory properties is supported by its capacity to
protect against the cumulative damaging effects of oxidative
stress(9), and inflammation(11), which affect the macula in condi-
tions such as age-related macular degeneration (AMD)(12–15). In
light of this evidence, the relatively recent emphasis on MP as a
possible ocular-protectant in diabetes(16), a pathological condi-
tion similarly associated with inflammation, oxidative stress
and progressive retinal damage, is logical and represents a natu-
ral extension of previous work in AMD(12–15).
The underlying molecular mechanisms associated with the
onset of diabetes and the potential protective effects of lutein
and/or zeaxanthin against retinal oxidative damage, inflamma-
tion and visual function have been explored in diabetic murine
Abbreviations: AMD, age-related macular degeneration; CAT, catalase; CRP, C-reactive protein; DiVFuSS, Diabetes Visual Function Supplement Study; GPx,
glutathione peroxidase; GSH, glutathione; MP, macular pigment; MPOD, macular pigment optical density; RCT, randomised controlled trial; RPE, retinal pigment
epithelium; ROS, reactive oxygen species; SOD, superoxide oxidase; VEGF, vascular endothelial growth factor.
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models(17–23). The onset of diabetes in alloxan and streptozotocin
diabetic mice and rats was accompanied by an increase in mark-
ers of oxidative stress and inflammation including: malondialde-
hyde, 8-hydroxy-2’deoxyguanosine, NF-B and vascular
endothelial growth factor (VEGF), with a concomitant decrease
in local antioxidants including glutathione (GSH) and gluta-
thione peroxidase (GPx)(17–19). Importantly, treatment with anti-
oxidants (lutein and/or zeaxanthin) has been shown to lower
oxidative stress and inflammation and increase endogenous anti-
oxidants; findings which in some(17,18) but not all(20) studies
occurred independently of any effects on hyperglycaemia.
The beneficial effects of these carotenoids on retinal function
have also been observed in diabetic murine models, and these
include the preservation of electro-retinogram b-wave ampli-
tude and prevention of neurodegenerative effects on the inner
retinal layers(17–19). Findings from these studies provide
important insights into the potential role that MP may have in
protecting against diabetic retinal disease; however, the
observed findings need to be interpreted with caution, as higher
MP dosages have been used in animal studies compared with
those used clinically in humans, and many of these studies have
never conclusively demonstrated retinal uptake of the adminis-
tered carotenoids beyond the retinal pigment epithelium (RPE)
and choroid(24,25). A summary of the experimental animal studies
examining MP optical density (MPOD) in diabetes is outlined in
Table 1.
A number of cross-sectional studies(16,26–29), including find-
ings from our own study group(28), and randomised controlled
trials (RCT)(30,31), have explored the relationship between type
1 and type 2 diabetes and MPOD in humans. MPOD is generally
found to be lower in diabetes(16,26,28), with some studies sug-
gesting that oxidative stress is implicated in its depletion(16,26).
Lower levels of MPODhave also been associatedwith raised gly-
cated Hb (HbA1c) levels and the presence of retinopathy in
patients with type 2 diabetes(16). In another study, patients with
diabetes (type 1 and 2) with grade 2 diabetic maculopathy had
significantly lower MPOD compared with those with no macul-
opathy (P= 0·016)(26).
Although oxidative stress is implicated as a causative factor,
the exact reasons why MP is lower in diabetes, and type 2 dia-
betes in particular(16,28), are not fully understood. One study
found lower levels of MP in type 2 v. type 1 diabetes(28), sug-
gesting that other coincident metabolic and pathological
abnormalities which are characteristic of type 2 diabetes (for
example, overweight/obesity, dyslipidaemia) may explain the
lower MPOD levels observed. Furthermore, lutein and zeaxan-
thin supplementation has been shown to exert positive and ben-
eficial ocular effects in those with diabetic eye disease, including
structural improvements in measures of macular oedema and
functional improvements in visual acuity and other visual func-
tion measures(30,31). Table 2 outlines a summary of the cross-
sectional studies and RCT examining the relationship between
MPOD and diabetes (type 1 and 2).
Although the evidence exploring MP and diabetes is rela-
tively sparse, the findings that have been reported are sufficient
to suggest that MPOD may be adversely affected by the condi-
tion, and that there is a plausible rationale to explore the possible
benefits of lutein and/or zeaxanthin supplementation for ocular
health and visual function in diabetes, particularly type 2. The
recent generation of such evidence has prompted this literature
review,which is designed to explore and elucidate themetabolic
perturbations and candidate causal mechanisms which may
underpin the likely complex interdependency of MP and dia-
betic eye disease (references used in Tables 1 and 2(16–23,26–36)).
Literature search methods
For the purpose of the present review, partly because of the rel-
ative dearth of higher-level RCT evidence, we have appraised all
forms of published research, even lower-level evidence sources,
to ensure that the scientific and clinical implications of the avail-
able evidence might be synthesised into useful treatise, which
accurately reflects what is known about this area, and what
remains to be elucidated. The review was carried out in two
stages. First, we identified all relevant published articles from
human and animal studies which reported on the relationship
betweenMP (lutein and/or zeaxanthin and/ormeso-zeaxanthin)
and diabetes (type 1 and type 2), up until the year 2019. The sec-
ond part of the search involved identifying publications which
investigated the relationship between the metabolic perturba-
tions typically associated with diabetes, and type 2 diabetes in
particular (for example, adiposity/dyslipidaemia) and MP. Pre-
selected keywords including ‘lutein’, ‘zeaxanthin’, ‘macular
pigment’, ‘diabetes’, ‘diabetes AND MP’, ‘diabetes AND lutein/
zeaxanthin’, ‘BMI’, ‘body fat AND diabetes’, ‘adipose’, ‘high den-
sity lipoprotein AND diabetes’, ‘triglycerides AND diabetes’,
‘oxidative stress’, ‘inflammation’, ‘hypertension AND MP’, ‘insulin
resistance’ and ‘hyperinsulinemia’ were entered into academic
databases and search engines including PubMed, Google
Scholar, Mendeley, Scopus, Cochrane Library and the ISRCTN
registry to define our search of the literature relating toMP and dia-
betes up until 2019. Although many supporting publications were
retrieved, in total, only eight animal studies (Table 1) and eleven
human studies (Table 2) were included to help clarify our current
understanding of the links between diabetes andMP. A total of thir-
teen papers on adiposity and MP (Table 3) and seven papers on
MP and dyslipidaemia (Table 4) were included to help analyse
the relationship between MPOD and the metabolic correlates of
type 2 diabetes (adiposity and dyslipidaemia). The overall findings
suggest that MP is lower in diabetes, type 2 diabetes in particular,
Fig. 1. Diagram highlighting the location of macular pigment and the macula
within the eye. For a colour figure, see the online version of the paper.
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and that supplementation with macular carotenoids and/or other
antioxidantsmay confer protection against diabetic eye disease. To
elucidate the causal mechanisms and metabolic perturbations
which might possibly explain the lower MP levels observed in dia-
betes, we will first explore the condition diabetes mellitus itself,
including its association with oxidative stress and inflammation;
and subsequently present the evidence linking adiposity and dys-
lipidaemia with type 2 (or poorly controlled type 1) diabetes
and MPOD.
Diabetes mellitus
Diabetes mellitus is a group of metabolic disorders caused by the
complex interaction of genetics, environmental factors and life-
style choices(37). Diabetes is characterised by a deficiency of
insulin and/or systemic insulin resistance. Over the past number
of decades, the number of individuals with diabetes, particularly
type 2 diabetes, has increased dramatically, making it a critical
and universal public health challenge(38). Type 1 diabetes usually
develops in normal-weight children, teenagers and younger
adults, and is an autoimmune condition involving the selective
destruction of pancreatic β-cells, ultimately resulting in complete
deficiency of insulin(39). Conversely, type 2 diabetes is linked to a
sedentary lifestyle and being overweight, and is characterised by
systemic insulin resistance and subsequent pancreatic endocrine
dysfunction, which results in attenuated insulin synthesis as well
as inhibition of its cellular effects(37). Whilst diabetes is character-
ised by having higher than normal blood glucose levels, the
pathogenesis and development of type 1 and type 2 diabetes
differ; therefore, the relationship between MPOD and the
different forms of diabetes should not be generalised. At presen-
tation, type 2 diabetes is most often accompanied by other co-
morbidities including overweight/obesity, insulin resistance,
hypertension and dyslipidaemia, features which are less
common in type 1 diabetes at diagnosis, but which may occur
as complications of type 1 diabetes later in the course of the
disease.Oxidative stress and inflammation are implicated in both
type 1 and type 2 diabetes; however, research has shown that
these metabolic disturbances are very pronounced in type 2
diabetes(40–44). The oxidative stress, inflammation, adiposity
and dyslipidaemia which characterise diabetes may have inde-
pendent relationships with MPOD, and therefore constitute
plausible causal mechanisms in diabetic eye disease. These
pathological mechanisms merit further exploration and will be
discussed in more detail herein.
Oxidative stress and diabetes
Chronic hyperglycaemia induces oxidative stress in patients with
diabetes(45). Oxidative stress, defined as the excessive produc-
tion of ROS, results in oxidative injury when the redox balance
is upset; i.e. where the level of oxidative species exceeds the
capacity of the antioxidant defence system to neutralise
them(46,47). ROS can include free radicals, which are partially
reduced oxygen species containing one or more unpaired elec-
trons (for example, superoxide anion or hydroxyl radical), and
species with their full complement of electrons in an unstable orTa
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reactive state (for example, singlet oxygen or H2O2)(48). The
body’s natural defence against oxidative damage is neutralisa-
tion by endogenous antioxidants(49), which include enzymic
antioxidants such as superoxide oxidase (SOD), catalase
(CAT) and GPx, and non-enzymic antioxidants such as GSH.
Our endogenous antioxidant defence system, however, is
incomplete without exogenous antioxidant nutrients including
vitamin C, vitamin E, carotenoids (β-carotene, lutein, zeaxan-
thin and meso-zeaxanthin) and polyphenols(50). Exogenous
antioxidants, such as those available in dietary fruit and
vegetables, are therefore necessary to balance redox status.
Through normal physiological processes, antioxidants inhibit
or quench free radical reactions and can delay or inhibit cellular
damage(46). When these processes are overwhelmed, however,
as in type 2 diabetes, ROS will readily react with lipids, proteins
and nucleic acids, resulting in impaired cell function or cell
death(51,52).
The retina is already at an increased risk of oxidative stress
and damage, given its high oxygen demand and consumption,
its exposure to visible light irradiation and its high concentration
of PUFA in the photoreceptor outer segments(53). These risks
increasewhen the generation of free radicals and ROS is stimulated
by environmental factors(54,55), short wavelength light exposure(56),
and other internal stresses including inflammation(57) and
hyperglycaemia(52,58,59). While PUFA in the photoreceptor
outer segment are thought to protect against oxidative and
inflammatory damage, they can potentially act as a substrate
for the propagation of free radicals as they provide a readily
available source of electrons(9,54). With increasing age, systemic
antioxidant levels decline and ROS levels increase in most tis-
sues, and this is associatedwith a number of neurodegenerative
diseases, including AMD and diabetes(9,26,60).
Hyperglycaemia, oxidative stress and changes in redox
homeostasis are fundamental events in the pathogenesis of dia-
betic retinopathy. Various mechanisms have been suggested to
contribute to the formation of reactive oxygen-free radicals.
Hyperglycaemia causes tissue damage through five major path-
ways, namely: increased flux of glucose and other sugars
through the polyol pathway; increased intracellular formation
of advanced glycation endproducts (AGE); increased expression
of the receptor for AGE (RAGE) and its activating ligands; activa-
tion of protein kinase-C isoforms; and activity of the hexosamine
pathway(61). Over-activation of these pathways can lead to dam-
age of cellular organelles and enzymes, increased lipid peroxi-
dation and the development of insulin resistance(62,63). Several
lines of evidence indicate that all five mechanisms are activated
by a single upstream event: mitochondrial overproduction of
ROS(64). Locally, the occurrence of these metabolic changes
results in defective angiogenesis and the activation of a number
of pro-inflammatory pathways which stimulate an influx of leu-
cocytes which can alter vascular permeability in the retina(21).
The role of hyperglycaemia in diabetic microvascular complica-
tions in the eye has been established by large-scale prospective
studies in type 2 diabetes (United Kingdom Prospective
Diabetes Study)(65). Beyond elevations in blood glucose, how-
ever, ROS formation is also increased by elevations in NEFA
(a common feature of type 2 diabetes), through their direct effect
on mitochondria(66).
While oxidative stress is increased in diabetes, the activities of
antioxidant defence enzymes responsible for scavenging free
radicals and maintaining redox homeostasis (SOD, CAT, GPx)
are concomitantly diminished in the retina of both type 1 and
type 2 diabetes(47,49,67). The activity of non-enzymic antioxidants
is also depressed during hyperglycaemia-induced oxidative
stress(67). Redox balance is important, as its disruption can cause
antioxidants to become pro-oxidative, potentially precipitating
damage to the retina. It cannot be assumed, however, that a sin-
gle reductive or antioxidant treatment would be sufficient to
reverse the underlying pathophysiological mechanisms of dia-
betic retinopathy. Antioxidant protection in the retina is provided
mainly from vitamins C and E, carotenoids, GPx, SOD and CAT
enzymes, and GSH compound(68), and many of these antioxi-
dants are aided by micronutrients (for example, Cu, Zn, Se)
which act as cofactors(69). The carotenoids lutein and zeaxanthin
are very effective quenchers of singlet molecular oxygen and
lipid peroxy radicals; however, in the process, these carotenoids
are themselves oxidised to their corresponding radical
cations(70). These cations must be reduced to regenerate the
original carotenoid, thereby allowing their reuse as an antioxi-
dant. Vitamin E (α-tocopherol) reduces oxidised carotenoids,
which leaves tocopherol oxidised(69). However, oxidised
tocopherol can be reduced and regenerated by vitamin C (ascor-
bic acid) and GSH, which are themselves further reduced by Cu
and Zn(15,71). Dietary lutein, zeaxanthin and vitamins E and C, as
well as endogenous antioxidant enzymes, therefore act in con-
cert with one another to lower the levels of ROS (via ROS detoxi-
fication) and to recycle oxidised lipid antioxidants (via
re-reduction).
The presence of oxidation products of the macular carote-
noids in human and primate retinal tissue indicates that lutein,
zeaxanthin and meso-zeaxanthin play an important antioxidant
role there(72). Zeaxanthin appears to be a more potent antioxi-
dant than lutein(73), withmeso-zeaxanthin evenmore efficacious,
but only in conjunction with its binding protein(74). Li et al.(75)
demonstrated that a 1:1:1 ratio mixture of lutein, zeaxanthin
and meso-zeaxanthin quenches more singlet oxygen than
any of these carotenoids individually at the same total
concentration(75,76), suggesting that they are most effective when
acting synergistically with one another. Diet is a major lifestyle
factor which can greatly influence the incidence and progression
of type 2 diabetes. Some dietary and lifestyle modifications asso-
ciated with enhanced antioxidant supply could therefore be an
effective prophylactic means to prevent or limit oxidative stress
in diabetic eye disease. Type 2 diabetes is associated with a sed-
entary lifestyle and being overweight; therefore, patients with
type 2 diabetes may not only be exposed to diets which are high
in fat and low in antioxidants(77), and to the increased oxidative
stress imposed by their diabetes(16,26,28), but may also be subject
to greater chronic oxidative stress as a result of their obesity
itself(78). The co-occurrence of these phenomena consequently
demands an even greater supply of exogenous antioxidants (vita-
mins C andE, carotenoids lutein, zeaxanthin andmeso-zeaxanthin)
to balance redox status and to combat this state of chronic oxidative
stress to which the diabetic retina is exposed. While the control of
blood glucose is critical in patients with diabetes, neuroprotec-
tive strategies and novel antioxidant treatments should also be
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considered to target the specific aetiologies and underlying
pathophysiological mechanisms of the condition, and to ulti-
mately protect against the vascular pathologies of diabetes. It
is logical that natural antioxidants (lutein, zeaxanthin and
meso-zeaxanthin) may have beneficial implications for diabetic
retinopathy in this context. However, larger trials involving
intensive assessment of oxidative stress, antioxidant defence
activities and their effects on one another in the diabetic state
are necessary before empirical supplementation of these caro-
tenoids can be recommended clinically.
Inflammation and diabetes
Diabetic retinopathy has traditionally been considered a disease
of the retinal microvasculature, associated with oxidative stress
induced by hyperglycaemia. More recently, however, inflamma-
tion has been cited as a deleterious factor in the development
of diabetic complications(79), and is now also implicated in
the pathogenesis of many ocular diseases including AMD(80)
and diabetic retinopathy(81). Numerous interplays exist
between inflammation and oxidative stress and vice versa(82).
Hyperglycaemia increases the levels of pro-inflammatory pro-
teins(79), and it is now believed that inflammatory processes
underlie many of the functional changes in retinal vasculature
observed histologically in early diabetic retinopathy, such as
pericyte loss, microaneurysms, and occluded and degenerated
capillaries(83).
While inflammation is normally a protective response to tis-
sue stress, hyperglycaemia leads to a dysregulation of inflamma-
tion, which ultimately becomes chronic. Oxidative stress triggers
inflammatory responses, and inflammation also enhances the
production of ROS, which creates a self-perpetuating cascade
towards oxidative tissue damage(84). The increased expression
of many inflammatory proteins in diabetic retinopathy is regu-
lated through the activation of pro-inflammatory transcription
factors including NF-κB(85). Activation of NF-κB leads to the syn-
thesis of pro-inflammatory molecules such as IL-1, IL-6, TNF-α,
c-Jun N-terminal kinase-1 (JNK-1), Iκ-B kinase-β (IKK-β) and
growth factors such as VEGF(21,85).
In the retina, the microvascular endothelium forms an effec-
tive barrier to control the movement of blood, fluid and proteins
across the vessel wall. This barrier is formed by tight junctions,
which consist of over forty different proteins and various inflam-
matory mediators including VEGF, TNF-α, protein kinase-C,
IL-1β and IL-6(83,86). Dysfunction of these proteins is highly cor-
related with the pathogenesis of blood retinal barrier breakdown
and increased vascular permeability, which leads to diabetic
macular oedema, a major cause of vision loss in diabetic
retinopathy(87). Inflammatory processes can induce oxidative
stress, and similarly, oxidative stress can induce inflammation
through the activation of multiple pathways. The coincident
over-activation of inflammation and oxidative stress can there-
fore deplete cellular antioxidant capacity and reduce MP levels
in the eye(9,88).
The expression of various pro-inflammatory cytokines, such
as TNF-α, IL-1 and IL-6, is also increased from visceral adipose
tissue (more common in type 2 diabetes), and this has been
linked to systemic inflammation and accompanying insulin resis-
tance(89). The inhibition of signalling downstream of the insulin
receptor is a primary mechanism through which inflammatory
signalling leads to insulin resistance(79). Several cross-sectional
studies have shown that insulin resistance and type 2 diabetes
are associated with higher levels of C-reactive protein (CRP),
IL-6 and TNF-α, all markers of subclinical inflammation(90–92).
Various longitudinal studies have also shown that elevated levels
of CRP and IL-6 are linked to the later development of type 2
diabetes(93,94).
Inhibition of different inflammatory mediators, including
NF-κB, IL-1β, VEGF and cyclo-oxygenase-2 (COX-2), has been
shown to limit the degeneration of retinal capillaries character-
istic of early-stage diabetic retinopathy(95). There is evidence
to suggest that lutein and zeaxanthin may prevent the develop-
ment of diabetic retinopathy by suppressing ROS induced by
inflammation(14). Li et al.(11) investigated the anti-inflammatory
effects of lutein on Muller cells in a murine model. Treatment
with lutein led to lower production of the pro-inflammatory fac-
tors NF-κB, IL-1β and COX-2, suggesting an anti-inflammatory
role for lutein in protection against retinal ischaemic/hypoxic
injury(11). In another study, the protective effects of lutein and
zeaxanthin against photo-oxidative damage to RPE cells were
investigated. Supplementation with carotenoids modulated the
inflammatory responses in these cultured RPE cells in response
to photo-oxidation(96).
The effects of zeaxanthin on diabetes-induced retinal oxida-
tive damage and inflammation have also been investigated in
diabetic rats(19). It was found that zeaxanthin significantly inhibits
diabetes-induced retinal oxidative damage and elevations in
VEGF and its adhesion molecule, abnormalities which are
commonly associated with the pathogenesis of diabetic
retinopathy(19). Clinical findings have highlighted the inverse
association between lutein and IL-6 in coronary artery disease
patients(97). A recent novel RCT, the Diabetes Visual Function
Supplement Study (DiVFuSS)(31), explored the effects of a nutri-
tional supplement (which included lutein and zeaxanthin) on
patients with type 1 and type 2 diabetes, and suggested that
the preparation used mitigated the damaging effects of systemic
inflammation on ocular function, and that these effects may have
been mediated by enhancements in MPOD. Chronic low-grade
inflammation and oxidative stress co-exist in diabetes, particu-
larly type 2 diabetes but also poorly controlled type 1 diabetes.
Therefore, findings from DiVFuSS, which achieved significant
increases in MPOD (27 % mean increase in DiVFuSS group v.
2 % mean decrease in placebo group), as well as reductions
in serum high-sensitivity CRP (60 % mean decrease in
DiVFuSS group v. 11 % mean decrease in placebo group),
may be due in part to the inclusion of compoundswhich, in com-
bination, specifically target both inflammation and oxidative
stress, and therefore, which block some of the oxidative
and/or inflammatory pathways responsible for the progression
of diabetic retinopathy(31). The inclusion of many compounds
in this test formula and the fact that both types of diabetic patients
(type 1 and 2) were examined renders interpretation of the out-
come more difficult; however, these findings are promising as
they clearly show that MPOD can be augmented in patients with
type 2 diabetes(31).
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While it is clear that oxidative stress and inflammation are
implicated in the initiation and development of diabetic reti-
nopathy, it remains unclear whether the pathological effects of
this oxidative stress/inflammation are mediated through
MPOD depletion in type 2 diabetes. The current body of evi-
dence which directly links lower MP levels with other metabolic
correlates of diabetes, namely adiposity and dyslipidaemia, will
now be explored to elucidate the possiblemechanisms bywhich
these metabolic factors mediate their effects on MPOD. It is
important to note that both increased adiposity and dyslipidae-
mia (primarily reduced HDL) may adversely affect MP by com-
promising the availability(98–101), and transport(102,103), of dietary
carotenoids to the retina. It follows that a condition such as type 2
diabetes, which unfavourably affects these parameters, may
have deleterious effects on MPOD, with clinically relevant out-
come effects. An analysis of the literature is presented describing
these putative mechanisms: (a) evidence in relation to MPOD
and body fat/adiposity (n 13; Table 3); and (b) evidence con-
cerning MPOD and dyslipidaemia (n 7; Table 4).
Type 2 diabetes, macular pigment optical density
and adiposity: the evidence
Diabetes mellitus is a chronic disorder which can alter carbohy-
drate, protein and fat metabolism. Weight gain, following exces-
sive energy intake, results in the body becoming markedly
resistant to the action of insulin. Despite initial impairment in
insulin action, glucose tolerance can remain normal for some
time because there is a compensatory increase in insulin secre-
tion by pancreatic β-cells, which results in a well-compensated
metabolic state, a condition known as hyperinsulinaemia.
There is now mounting evidence to indicate that persistently
elevated plasma insulin levels can contribute to the development
of hypertension, plasma lipid abnormalities and atherosclerosis(104).
The escalating rates of insulin secretion as a result of advancing
obesity, however, cannot be maintained and type 2 diabetes
ensues.
Intra-abdominal fat appears to be an important determinant
of insulin sensitivity compared with subcutaneous fat(105).
Visceral fat and subcutaneous fat differ in their phenotypic,
physiological and functional aspects, as there are a greater num-
ber of macrophages, T lymphocytes and pro-inflammatory mol-
ecules in visceral v. subcutaneous fat in obese individuals.
Abdominal adipose tissue produces a variety of adipocytokines
including IL-1, IL-6, IL-8, TNF-α, leptin and resistin; therefore, the
abdominal adiposemass acts as an important mediator of inflam-
mation in diabetes(106). Obesity also leads to an increased size of
adipocytes. The death of adipocytes, which is rare in healthy
individuals, is very common in obese individuals and has been
linked to adipocyte hypoxia. The accumulation of macrophages
in the adipose tissue of obese individuals not only eliminates the
dead cells but also further increases their synthesis of inflamma-
tory mediators IL-8, IL-6, IL-1 and TNF-α(106). The resultant
inflammation becomes chronic; therefore, obesity is considered
a low-grade inflammatory condition which in turn leads to an
increase in oxidative stress. Serum 8-hydroxy guanosine
(8-OhdG), a known sensitive marker of oxidative DNA damage
and of total systemic oxidative stress in vivo, has been shown to
be positively correlated with BMI in individuals with type 2 dia-
betes mellitus(107). Over-expression of oxidative stress, and the
concomitant reduction in antioxidant defence, damages cellular
structures(108), often resulting in further inflammatory responses.
Antioxidant defences may be lower in overweight/type 2 dia-
betic patients, due to their lower intake of antioxidant-rich foods
(for example, fruits and vegetables), their increased utilisation of
these molecules (for example, increased inflammation/ROS in
insulin-dependent tissue such as the retina) and their impaired
generation of other supportive antioxidants(108), factors which
may collectively lead to MPOD depletion.
The diminished response to insulin in type 2 diabetes also
leads to increased lipolysis in adipocytes. Enlarged adipocytes
release NEFA and adipocytokines(67,104); therefore greater
amounts of NEFA reach the liver via the portal vein, resulting
in fatty liver infiltration. Mobilised NEFA are oxidised by vascular
endothelium to generate ROS. Elevations of NEFA in serum also
inhibit insulin suppression of hepatic glucose production, lead-
ing to an increase in glucose production by the liver(109). This, in
turn, results in both insulin resistance and inflammation in the
major insulin target tissues (skeletal muscle, liver and endothelial
cells). Abnormal levels of lipids, fatty acids and various adipocy-
tokines from adipose tissue therefore initiate a vicious cycle of fat
damage, inflammation, worsening insulin resistance, impaired
β-cell insulin secretion and ultimately type 2 diabetes(104,110).
The chronic low-grade inflammation associated with obesity
and type 2 diabetes leads to increased oxidative stress and fur-
ther inflammation, putting a greater demand on antioxidant
defences.
Apart from its pro-inflammatory and pro-oxidant effects, adi-
pose tissue is also a major body store for carotenoids such as
lutein and zeaxanthin. Higher levels of body fat have been
shown to be related to lower levels of circulating carote-
noids(111), making these pigments less available to retinal tis-
sue(112). Furthermore, a randomised controlled weight loss trial
found that a significant weight loss in the intervention group
was related to increases in serum lutein(113). Higher BMI(114)
and higher body fat percentage(101) have both been linked with
an increased risk of AMD. Studies have reported an inverse rela-
tionship between adiposity and BMI and MPOD(99,115), with the
observed relationships largely attributable to participants with a
BMI > 29 kg/m2(99). One study found that higher body fat per-
centage, even within relatively healthy limits, was associated
with lower retinal tissue lutein and zeaxanthin status(116), sug-
gesting that adiposity may affect the nutrient status of the retina.
Sex differences in MPOD have also been reported(98,101), which
may imply differences inmetabolism ofMP, or reflect differences
in adipose tissue storage of these dietary carotenoids between
men and women. Competitive absorption by a larger overall
fat mass (percentage fat mass is generally higher in women)(117),
or specifically by greater abdominal fat mass (which is more
common in men)(118), may reduce lutein and zeaxanthin uptake
by the retina. Concentrations of carotenoids differ according to
body site, with levels demonstrably higher in abdominal fat(119),
which may explain the differences in MPOD currently observed
between men and women(98,101). Since adipose tissue may trap
lutein and zeaxanthin(116), individuals who are overweight or
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obese (type 2 diabetes) may consequently have lower concen-
trations of the carotenoids lutein and zeaxanthin available at the
macula.
Overall, the research appears to suggest that obesity has a
negative impact on MPOD; however, there is also some evi-
dence to the contrary. One study found that mean MPOD values
did not differ significantly between subjects with various types of
obesity and ideal-weight subjects(120). Our previous study(28) is
the only one to date which has examined the relationship
between BMI and MPOD in a group with diabetes. This study
found that MPOD was significantly lower and BMI was signifi-
cantly higher in patients with type 2 diabetes, compared with
type 1 and non-diabetic controls, highlighting the possibility that
different relationships exist between MPOD status and type 1
and 2 diabetes. The higher BMI levels observed in type 2 diabe-
tes are reflective of excess adiposity which acts as a store for
lutein and zeaxanthin. However, as described previously,
obesity is also independently associated with increased oxida-
tive stress(108,121,122), and with inflammation(123) which exacer-
bates oxidative stress, and may therefore have multiple
depletive effects on MP. Unfortunately, the cross-sectional
nature of this study(28) means that it cannot elucidate the extent
or nature of any causal relationships between BMI and MPOD in
these type 2 subjects.
The different presenting features of type 1 and 2 diabetes,
and the interplay of their disease components with MPOD status
(for example, adiposity), may mean that the mechanistic rela-
tionship between these conditions and MPOD status is not uni-
form across both. The fact that much of the research to date
includes both diabetic groups may obfuscate any relationships
present. Although the evidence to date is somewhat conflicting,
there appears to be a theoretical basis for a relationship between
the characteristic body fatness of type 2 diabetes and lower
levels of MPOD. A summary of the studies investigating the
association between MPOD and adiposity are outlined in
Table 3(28,29,98,99,101,113,115,116,120,124–127).
Type 2 diabetes, macular pigment optical density
and dyslipidaemia: the evidence
Insulin resistance and obesity, metabolic abnormalities com-
monly associated with type 2 diabetes, may themselves lead
to disturbances in the production and clearance of plasma
lipoproteins(128). Dyslipidaemia is often characterised by low
levels of HDL and hypertriacylglycerolaemia. In addition,
LDL particles are converted to smaller, more atherogenic
lipoproteins(129). A number of factors are likely to be responsible
for diabetic dyslipidaemia and these include insulin’s effects on
liver apoprotein production, dysregulation of lipoprotein lipase
(LPL), impaired action of cholesteryl ester transfer protein and
the peripheral action of insulin on adipose and muscle(128).
Hormone-sensitive lipase and LPL are two enzymes that regulate
mobilisation and deposition of fatty acids in adipose tissue in a
reciprocal manner(130). Reduced insulin action leads to increased
lipolysis in adipocytes with increased NEFA release, which can
mediate many adverse metabolic effects, most notably further
insulin resistance(110) and dyslipidaemia(128). In diabetes greater
amounts of fatty acids returning to the liver are reassembled into
TAG and secreted in VLDL(131). In the presence of increased con-
centrations of VLDL in circulation, cholesteryl ester transfer
protein will exchange VLDL TAG for cholesteryl ester in the core
of HDL, which results in smaller HDL particles, which are more
rapidly cleared from plasma(132). This explains the hypertriacyl-
glycerolaemia and reduced HDL commonly observed in type 2
diabetes(128). Cholesteryl ester transfer protein also exchanges
VLDL TAG for cholesteryl ester in the core of LDL and the net
effect is a decrease in the size and an increase in the density of
LDL particles(128). In vitro, small dense LDL can be oxidised more
easily, and it binds to LDL receptors less avidly than normal LDL.
As a result, diabetic patients are at an increased risk of CVD. Many
clinicians measure LDL density and/or size to predict risk of CVD.
An increase in waist circumference and waist:hip ratio has been
found to be associated with small dense LDL particles(128,133).
Therefore, intra-abdominal fat is a critical determinant of an athe-
rogenic lipoprotein profile, including disruptions in the distribu-
tion of cholesterol in the different lipoprotein fractions(105).
The characteristic lipid profile in an individual with type 2 dia-
betes (increased serum VLDL, increased TAG, decreased serum
HDL and less commonly, an increase in LDL-cholesterol)(128)
may have important implications forMP levels in the eye, as studies
have shown that the carotenoids lutein and zeaxanthin are pri-
marily transported byHDL in plasma(102,103). HDL is a known ligand
for scavenger receptor B type 1 (SR-B1), and this suggests a ‘piggy-
back’mechanismof lutein and zeaxanthin uptake into the retina via
RPE cells which is mediated by SR-B1(134). This hypothesis is sup-
ported by evidence from lutein deficiencies observed in the retina
of chickens with a genetic HDL defect but not in other organs,
implying a major role for HDL in the receptor-mediated transport
of lutein to the eye(102). It has been argued that the subspecies of
HDL containing apoE supplies lipids and lipid-soluble lutein and
zeaxanthin to the retina, and that by increasing HDL, retinal lutein
levels may be simultaneously augmented(100).
n-3 Long-chain PUFA supplementation may also lead to
increases in serumHDL(135). Recent epidemiological studies indi-
cate that increased dietary long-chain-PUFA intakes enhance
MPOD(136), and that DHA facilitates the accumulation of lutein
in the blood and macula. The mechanism by which DHA
increases MPOD may relate to its effect on the transport and
uptake of lutein into the macula by mediating changes in lipo-
protein levels(137). Putatively, this effect could also be mediated
by the anti-inflammatory effects of DHA, but this is conjectural
and no direct evidence supports this effect within the retina.
One observational study found that the correlation between
MPOD, serum lutein, zeaxanthin and lipids differed depending
on the age profile of participants(138). In younger adults, MPOD
was found to be influenced by serum lutein, whereas in older
adults, circulating lipids were an added determining factor(138).
Mares et al.(29) queriedwhether any associationwith serum lipids
is truly strong enough to play a meaningful role in the pathogen-
esis ofMPODdepletion.One studywhich used a diabetic cohort,
involving a small group of forty-three participants (fourteen con-
trols, seventeen with diabetes but without retinopathy
and twelve with diabetes and with mild non-proliferative reti-
nopathy), found no significant correlation between MPOD
and serum lipid levels(16). Our own research group(28), however,
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reported lower levels of MPOD in type 2 v. type 1 diabetics and
noted significantly lower HDL values within the type 2 group,
raising the possibility that lower HDL levels may have contrib-
uted to this difference. More recently, the DiVFuSS study(31)
has demonstrated significant improvements in serum LDL-cho-
lesterol level (9 % mean decrease in the intervention group v.
1 % mean increase in placebo group), HDL-cholesterol (7 %
mean increase in the intervention group v. 3 % decrease in pla-
cebo group) and TAG (8·6 % mean decrease in the intervention
group v. 2 % mean increase in placebo group), suggesting a
positive effect of the study formulation on serum lipids. Whilst
this effect was probably attributable to other non-carotenoid
components of the supplement, the synchronous increase in
MPOD observed in the intervention group may have been par-
tially mediated by these favourable changes in lipid profile and
their consequential impact on carotenoid transport to the
retina(102,103,139). In the broader context, the evidence from this
study is sufficiently robust to prompt further lines of investigation
into the role of MP supplementation either in isolation or as a
multi-component supplement in diabetes. The research to date,
however, is not conclusive and it remains unclear from the lim-
ited amount of observational and RCT data whether serum lipids
(primarily HDL) play a meaningful role in determining MPOD
status. Given the theoretical basis for an association between
lipid profile and MP status, and the fact that lipid profile is often
altered deleteriously in diabetes, further investigation is war-
ranted. The relationship between dyslipidaemia and lower levels
of MP is outlined in Table 4(16,29,31,138–141).
Causal mechanisms and metabolic perturbations
associated with lower macular pigment in diabetes
The candidate causal mechanisms explored herein as contribu-
tors to lower MPOD levels in diabetes relate primarily to type 2
diabetes (or poorly controlled type 1). The complex inter-
relationship between oxidative stress/inflammation and the
metabolic correlates of diabetes (adiposity, dyslipidaemia, insu-
lin resistance, hyperinsulinaemia and hyperglycaemia), and their
associations with MPOD, both individually and as a whole,
represent a significant scientific challenge. In summary, our
analysis indicates that MPOD might be depleted through at least
four causal mechanisms previously described, all of which are
outlined in Fig. 2.
Dietary determinants of macular pigment optical density
in diabetes
First and foremost, patients with type 2 diabetes may experience
lower levels of MP as a result of poor dietary intake of antioxidant
nutrients (lutein, zeaxanthin and meso-zeaxanthin). Lutein and
zeaxanthin are not synthesised de novo in humans; therefore,
a diet rich in fruit and vegetables is necessary to enhanceMP lev-
els in the eye(4). While the exact cause of diabetes is still not fully
understood, dietary factors have garnered particular attention
over the last number of years. In fact, some research indicates
that up to 74 % of type 2 diabetes cases are directly attributable
to obesity(142).
Fig. 2. Metabolic perturbations and supply deficiencies contributing to macular pigment depletion in diabetes. MPOD, macular pigment optical density; ROS, reactive
oxygen species. For a colour figure, see the online version of the paper.
Lower macular pigment in diabetes mellitus 11
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S095442241900012X
Downloaded from https://www.cambridge.org/core. Dublin Institute of Technology, on 14 Aug 2019 at 08:15:21, subject to the Cambridge Core terms of use, available at
Many studies have reported a positive association
between a high intake of sugars and the development of type 2
diabetes(143–145). Research has also found an association between
high fat intakes and type 2 diabetes and impaired glucose
tolerance(146,147), with some literature suggesting that high-fat,
low-carbohydrate diets are associated with the onset of type 2
diabetes(146). A global change in dietary intake has occurred over
recent decades resulting froman increaseduseof sweeteners such
as fructose and sucrose by the food industry(148). Recent evidence
suggests a causal linkbetween thehigh intakeof sugar-sweetened
soft drinks and obesity and diabetes. This is thought to arise from
the large amount of fructose in these soft drinks, which impairs
insulin sensitivity and raises blood glucose levels and BMI to
dangerous levels(144,149). Fructose consumption increases post-
prandialTAGconcentrationswithinhours(150),which suggests that
postprandial hypertriacylglycerolaemia is one of the earliest
metabolic perturbations associated with fructose consumption.
The most likely mechanism for this hypertriacylglycerolaemia is
increased hepatic de novo lipogenesis, which in turn up-regulates
VLDL production and secretion(151), factors which have a
knock-on suppressive effect on HDL, a known transporter of
carotenoids to the eye(102,103).
Studies have also found an inverse correlation between the
intake of green leafy vegetables and risk of developing type 2
diabetes(152,153), and that the consumption of fruits and vegeta-
bles may protect against the development of type 2 diabetes,
as they are rich in micronutrients, fibre and antioxidants(153),
dietary components also known to enhance MPOD. A recent
meta-analysis revealed that a higher intake of fruit, especially
berries and green leafy vegetables, yellow vegetables and crucif-
erous vegetables or their fibre, is associated with a lower risk of
type 2 diabetes(152). Health benefits have also been observed
with the Mediterranean diet(154,155), a diet which contains an
abundance of fruit and vegetables. While the beneficial effects
of fruits and vegetables on diabetes risk are likely to be multiple,
these foods are the primary dietary source of carotenoids
including lutein and zeaxanthin, highlighting their consumption
as a key determinant of MPOD. Lower levels of MPOD in
diabetes might also be associated with high intakes of fried
foods and fat(156), alcohol(157), red and processed meat(158),
sugar-sweetened beverages(143,144) and high-glycaemic index
foods(159), all of which have been linkedwith higher levels of vis-
ceral fat and increased waist circumference. Numerous studies
have shown that obesity (in particular, central obesity) can
increase the risk of type 2 diabetes(160).
While the body’s natural defence against oxidative damage
and inflammation is neutralisation by endogenous antioxi-
dants (enzymic and non-enzymic), in association with exog-
enous antioxidants (vitamin C, vitamin E, carotenoids,
β-carotene, lutein, zeaxanthin and meso-zeaxanthin)(50,68),
these antioxidant defences may be compromised in diabetes.
Hence, it is clear that both over-utilisation and under-supply
of antioxidant nutrients may contribute to lower levels of MP
in the diabetic retina.
Based on the outlined associations between nutritional and
dietary factors and the components of the metabolic syndrome
which may contribute to MPOD depletion, we outline dietary
factors which: (1) may exacerbate the metabolic correlates asso-
ciated with type 2 diabetes (Table 5 column a); and (2) may help
to prevent or resolve themetabolic perturbations associatedwith
type 2 diabetes (Table 5 column b).
Overall, Western dietary habits are a significant factor in the
development of the metabolic syndrome. The continuous over-
provision of energy via dietary carbohydrate and lipid, when
unmatched by physical activity-induced energy expenditure,
leads to a state of excess adiposity, chronic low-grade inflamma-
tion, and oxidative stress and dyslipidaemia; features associated
with type 2 diabetes and which may lead to MPOD depletion.
The importance of diet cannot be overemphasised in diabetes
management. Given the variety of mechanisms which may con-
tribute toMPODdepletion and the broader ocular risks associated
with such MPOD depletion in diabetes, a comprehensive dietary
Table 5. Dietary factors associated with the metabolic correlates of type 2 diabetes mellitus
Metabolic
correlates of type
2 diabetes
(a) Causal dietary factors associated with the
metabolic correlates of type 2 diabetes
(b) Preventative dietary factors associated with the
metabolic correlates of type 2 diabetes
Oxidative stress High protein (red meat)(158), high fat (saturated fat)(161,162),
high carbohydrate (refined sugar, fructose)(143,144,163)
Whole grains (fibre)(164), nuts (fibre, n-3 PUFA)(165).
Fruit and vegetables (antioxidants vitamins C and E,
β-carotene, lycopene, quercetin, resveratrol, flavonoids, lutein,
zeaxanthin and meso-zeaxanthin)(4,12,15,30,31,70,152,153,155,166,167).
Fish (n-3 PUFA)(168), legumes (protein, phytochemicals)(169)
Inflammation High fat (saturated fat, trans-fat)(170–172), high carbohydrate
(refined sugar, fructose)(163,173,174), alcohol(175)
Oily fish and n-3 FA(168), folate(176), vitamin D(177).
Fruit and vegetables (antioxidants vitamins C and E,
β-carotene, lycopene, quercetin, resveratrol, flavonoids, lutein,
zeaxanthin and meso-zeaxanthin)(14,166)
Obesity High energy-dense foods(178), high fat (saturated)(179–182), high
carbohydrate (refined sugar, fructose)(143,144)
Diet and exercise(183), high dietary fibre(184).
High fruit and vegetable intake (antioxidants vitamins C and E,
β-carotene, lycopene, quercetin, resveratrol, flavonoids, lutein,
zeaxanthin and meso-zeaxanthin)(166), high milk intake(185)
Dyslipidaemia High fat (saturated fat, trans-fat)(186–188), high carbohydrate
(refined sugar, fructose)(189,190), Na(189), alcohol (especially
binges)(191), low physical activity(192)
High dietary fibre(184), n-3 FA(193,194), plant stanols/sterols(195),
physical activity(135,192)
FA, fatty acids.
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approach is therefore necessary to optimise ocular health and
MPOD status. The generous provision of brightly coloured
fruits and vegetables which are rich in a broad range of antioxi-
dants including the target carotenoids lutein, zeaxanthin and
meso-zeaxanthin represents an obvious recommendation. This,
however, should be complemented by the inclusion of whole-
grain-fortified breakfast cereals for their folate, vitaminD and anti-
obesogenic fibre content; and with plenty of oily fish to provide
further vitamin D and n-3 essential fatty acids to attenuate inflam-
mation and correct or prevent hypertriacylglycerolaemia. These
foods should be used to displace those which are high in fat, satu-
rated fat, refined sugar and fructose; for example, oily fish should
replace red or processed meats at several main meals each week,
fruit or rawvegetables should be used to replace snack foods high
in fat, saturated fat, trans-fat and refined sugar (for example,
baked goods and confectionery), and low-fat fortifiedmilk should
replace sugar-sweetened soft drinks. Starchy carbohydrates
should be evenly distributed over the day to achieve better
glycaemic control, with sterol- or stanol-enriched products used
to reduce serum LDL and consequently enhance LDL:HDL ratio.
Finally, from a broader lifestyle perspective, these individuals
should be advised to moderate their alcohol consumption to
no more than two standard drinks per d with several alcohol-free
days each week, and to engage in moderate-intensity exercise
(for example, walking) onmost days of the week to enhance their
insulin sensitivity and optimise their blood glucose and lipopro-
tein profiles. Table 5 (column a) outlines the dietary factors
causally associated with the metabolic correlates of type 2
diabetes, and Table 5 (column b) outlines the dietary factors asso-
ciated with protection against the metabolic perturbations of type
2 diabetes.
Conclusion
The present review outlines our current understanding of the
relationship between diabetes and MPOD. MP appears to be
generally lower in diabetic populations compared with healthy
controls(16), and this is noted particularly amongst patients with
type 2 diabetes(28). Impaired defence against reactive oxidative
species (ROS) at the retina may not only be attributable to lower
intake of foods rich in carotenoids and other antioxidants
(for example, fruit, vegetables, legumes), however, but may also
arise from the increased utilisation of these antioxidants in
diabetes (via chronic inflammation and oxidative stress).
Adiposity, particularly abdominal fatness, is closely linked to
type 2 diabetes, and is a significant factor in the condition’s
pathogenesis. Excess fat tissue may not only compete with the
retina for uptake of dietary carotenoids, but may also contribute
to increased oxidative stress and inflammation, factors which
may have a negative impact on MP levels in the eye. Similarly,
the hyperglycaemia which is characteristic of diabetes also
contributes to inflammation and oxidative stress, and their
depletive effects on MPOD. Dyslipidaemia, more common in
poorly controlled diabetes, is a metabolic correlate which may
adversely affect the transport and assimilation of carotenes into
retinal tissue, by limiting the availability of their principal carrier
HDL. The chronic low-grade inflammation and increased oxida-
tive stress observed in patients with type 2 diabetes may also
increase the use of these carotenoids at the molecular level,
and, in so doing, may elevate our dietary requirement for them.
It is important to note the significant limitations which cur-
rently prevail in the reviewed literature. The heterogeneity of
studies is a major drawback. Small sample sizes, the merging
of type 1 and type 2 diabetic patients in statistical analyses,
and the complex interplay of diabetes and its accessory factors
(adiposity, dyslipidaemia, oxidative stress and inflammation)
with MPOD status are also challenging. While there is some
preliminary positive evidence, primarily from animal
studies(19,20) and the DiVFuss trial(31), that higher MP levels
may be protective against retinal damage, there is limited
evidence that low MPOD levels are detrimental to ocular
health in diabetes, and the actual benefits of higher MPOD
in terms of retinal disease development and/or progression
in diabetes remain to be elucidated.
In view of the limited evidence available, supplementation
with lutein, zeaxanthin and/or meso-zeaxanthin, either
with or without other antioxidants, represents a fertile area
for future interventional research. It is important to recognise,
however, that in order to minimise the risk of MPOD depletion
and/or ocular damage in diabetes, it is not sufficient to simply
supplement with macular carotenoids. Rather, our review
suggests the need for a more holistic evaluation of diet and
lifestyle in relation to MPOD in diabetes. In this context,
inflammation and oxidative stress, the dual pathogenic
driving forces of diabetes which occur independent of hyper-
glycaemia, may be amenable to dietary intervention and nutri-
tional supplementation. The incorporation of a number of
dietary modifications (for example, enhanced antioxidant,
vitamin D and n-3 fatty acid intake; and reduced fat, saturated
fat, trans-fat and refined sugar consumption), alongside
lifestyle changes such as increased physical activity, may
not only address the under-supply of macular carotenoids,
but may also abrogate the competitive storage, transport,
inflammatory and oxidative features of type 2 diabetes which
may compromise MPOD status. The safety and low cost of
such interventions further commend their potential value as
a therapeutic adjunct in diabetic eye disease, and may come
to represent an essential element of ocular care for this impor-
tant and expanding patient group.
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